Business

Synthaverse Receives Marketing Authorization For Onko BCG Drug In The Netherlands

Synthaverse Receives Marketing Authorization For Onko BCG Drug In The Netherlands

Synthaverse Spolka AkcyjnaNovember 13, 20254
Synthaverse Receives Marketing Authorization For Onko BCG Drug In The Netherlands

About this update from Synthaverse Spolka Akcyjna

Synthaverse SA GPW:SVE:RECEIVES MARKETING AUTHORIZATION FOR ONKO BCG DRUG IN THE NETHERLANDS

View stock analysis, news, and events for Synthaverse Spolka Akcyjna